IXIFI Drug Profile

Summary for Tradename: IXIFI

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for IXIFI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for IXIFI Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for IXIFI Derived from Patent Text Search

No patents found based on company disclosures

IXIFI Market Dynamics and Financial Trajectory: Infliximab Biosimilar Analysis

Last updated: September 8, 2026

IXIFI, Pfizer’s infliximab-qbtx biosimilar to Remicade, entered the U.S. market after Remicade’s core exclusivity period had ended and into a crowded anti-TNF biosimilar segment. Its commercial position has been constrained by established competitors, payer-driven substitution, physician familiarity with earlier infliximab biosimilars, and the absence of separately reported product revenue. Pfizer does not disclose IXIFI sales as an individual line item, so its financial trajectory must be assessed through market structure, product access, and Pfizer’s broader biosimilars disclosures.

What is IXIFI and when did the FDA approve it?

IXIFI is an intravenous infliximab biosimilar developed and marketed by Pfizer. The reference product is Remicade, Johnson & Johnson and Janssen’s infliximab biologic.

Item	IXIFI data
Active ingredient	Infliximab-qbtx
Reference product	Remicade, infliximab
Sponsor	Pfizer
FDA application	BLA 761072
FDA approval	December 2017
Dosage form	Intravenous infusion
Therapeutic class	Tumor necrosis factor, or TNF, blocker
FDA biosimilar status	Biosimilar to Remicade
Interchangeability	Not designated interchangeable by FDA
Main indications	Rheumatoid arthritis, Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, pediatric ulcerative colitis, plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis

The FDA approved IXIFI for the same principal indications as Remicade based on analytical, pharmacokinetic, immunogenicity, and clinical similarity data. The approval did not create a new mechanism of action or a differentiated delivery system. IXIFI remains dependent on infusion-center administration and physician or facility purchasing decisions. (U.S. Food and Drug Administration, 2017)

How does IXIFI compare with competing infliximab biosimilars?

IXIFI competes primarily with Inflectra and Renflexis in the United States. Inflectra, marketed by Pfizer’s Hospira business, was the first FDA-approved infliximab biosimilar. Renflexis was developed by Samsung Bioepis and commercialized in the United States through Merck.

Product	Active ingredient	U.S. approval	Principal commercial sponsor	Interchangeability designation
Remicade	Infliximab	1998	Janssen / Johnson & Johnson	Reference biologic
Inflectra	Infliximab-dyyb	2016	Pfizer / Hospira	No
Renflexis	Infliximab-abda	2017	Samsung Bioepis / Merck	No
IXIFI	Infliximab-qbtx	2017	Pfizer	No

IXIFI faced a commercial disadvantage because Pfizer already had Inflectra in the same molecule class. A hospital or payer evaluating Pfizer’s portfolio could favor the earlier product because it had longer market experience, established contracting arrangements, and existing physician familiarity. IXIFI therefore had limited ability to create a distinct franchise without a meaningful price, supply, or contracting advantage.

What is the market size for infliximab biosimilars?

The U.S. market for infliximab was historically worth several billion dollars annually at the branded Remicade level. Johnson & Johnson reported global Remicade sales of approximately $5.3 billion in 2017, before biosimilar erosion became fully reflected in the product’s financial performance. Remicade revenue declined materially in subsequent years as Inflectra, Renflexis, and IXIFI competed for hospital, physician-office, and payer-controlled volume. (Johnson & Johnson, 2018, 2021, 2023)

The addressable market is divided among:

• Rheumatology infusion centers
• Gastroenterology practices
• Hospital outpatient departments
• Specialty pharmacies and buy-and-bill providers
• Commercial insurers
• Medicare and Medicaid
• International tender markets

The commercial value of the market is lower than the historical Remicade market because biosimilar pricing reduced average net selling prices. Volume growth in inflammatory bowel disease and other immune-mediated conditions partly offsets price erosion, but the market has shifted from branded premium pricing to contracting and channel economics.

What is IXIFI’s financial trajectory?

Pfizer does not publicly report IXIFI revenue, gross margin, unit volume, market share, or operating profit separately. The product is included within broader Pfizer biosimilar, hospital, or established-products reporting categories, depending on the reporting period and segment presentation.

The available financial picture is therefore:

Financial metric	Publicly disclosed IXIFI result
Annual product revenue	Not separately disclosed
U.S. market share	Not consistently disclosed by Pfizer
Average selling price	Not disclosed
Gross margin	Not disclosed
Development spending	Not separately disclosed
Commercial launch investment	Not separately disclosed
Product-specific forecast	Not publicly disclosed

IXIFI’s likely financial trajectory has four stages:

1. Development and approval period: Pfizer incurred biosimilar development, regulatory, manufacturing, and legal costs before commercial revenue began.
2. Early market entry: Revenue potential was limited by the presence of Inflectra and Renflexis and by the time required for payer and provider adoption.
3. Price competition: As multiple infliximab biosimilars competed, net prices declined and contracting became more important than regulatory differentiation.
4. Mature portfolio economics: IXIFI’s value depends on retained contracts, manufacturing efficiency, supply reliability, and Pfizer’s ability to use its broader biosimilar portfolio to negotiate with health systems and payers.

The product is unlikely to have become a major standalone revenue driver for Pfizer. Its strategic value is better measured as part of Pfizer’s biosimilar portfolio and as a contributor to manufacturing scale, payer access, and hospital contracting.

When did IXIFI lose exclusivity and what patents protected Remicade?

Remicade’s principal U.S. composition-of-matter patent, U.S. Patent No. 6,284,471, expired in 2018. The patent covered antibodies and related technology associated with infliximab. Additional patents and regulatory exclusivities affected the timing and terms of biosimilar entry, including formulation, manufacturing, and method-of-treatment claims.

The practical exclusivity timeline was:

Milestone	Date or period
Remicade FDA approval	1998
Original biologic exclusivity framework	Before modern BPCIA exclusivity
U.S. composition patent expiration	2018
Inflectra approval	2016
Renflexis approval	2017
IXIFI approval	2017
Broad commercial biosimilar competition	2018 onward

Unlike a small-molecule drug, IXIFI is not listed in the FDA Orange Book. Biologic patent and exclusivity information is tracked through the FDA Purple Book and through patent litigation and settlement records. The FDA Purple Book identifies reference products, biosimilars, and interchangeability status but does not provide the same complete patent-listing function as the Orange Book. (U.S. Food and Drug Administration, 2024)

What formulation patents and manufacturing barriers affect IXIFI?

IXIFI has no publicly recognized formulation feature that materially separates it from other intravenous infliximab products. Its principal technical barriers are biosimilar-development and manufacturing barriers rather than a differentiated dosage form.

Relevant barriers include:

• Cell-line development and control
• Mammalian-cell culture consistency
• Protein folding and glycosylation control
• Aggregate and impurity control
• Analytical similarity testing
• Immunogenicity monitoring
• Sterile fill-finish capacity
• Cold-chain distribution
• Batch release and pharmacovigilance
• Comparability after manufacturing changes

For a monoclonal antibody, manufacturing consistency can protect commercial economics even after composition patents expire. A biosimilar manufacturer must maintain a validated process and secure reliable supply across multiple infusion channels. Product failures, shortages, or batch variability can cause permanent loss of provider confidence.

Manufacturing protection is not equivalent to patent exclusivity. It is an operational barrier that can influence market share but generally does not prevent a capable competitor from entering.

Which companies are challenging the Remicade franchise?

The principal U.S. competitors are Pfizer, Samsung Bioepis, Merck, and Janssen. Pfizer occupies two positions through Inflectra and IXIFI, which creates both scale advantages and portfolio overlap.

Competitive landscape

Pfizer’s competitive position rests on:

• Existing hospital and specialty-care relationships
• Experience commercializing Inflectra
• Global manufacturing and distribution capacity
• Ability to bundle products across its biosimilar portfolio
• Familiarity with payer and provider contracting

Samsung Bioepis and Merck compete through Renflexis, while Janssen protects the Remicade franchise through contracting, clinical familiarity, and the residual value of the reference product brand.

The most important competitive variables are usually:

1. Net price after rebates
2. Payer formulary placement
3. Provider acquisition cost
4. Buy-and-bill reimbursement
5. Distribution reliability
6. Patient support services
7. Physician comfort with switching
8. Immunogenicity and real-world evidence

What is the Paragraph IV and litigation risk for IXIFI?

IXIFI’s principal patent risk was tied to the Remicade patent estate and the BPCIA patent-resolution process. Biosimilar applicants may trigger patent disputes through notice procedures and patent challenges, including invalidity, unenforceability, or non-infringement arguments.

The commercial significance of litigation was greater before and during launch than after broad infliximab biosimilar entry. Once several biosimilars were approved and the core Remicade composition patent had expired, the market’s principal risks shifted from blocking litigation to pricing, contracting, and substitution.

Publicly available information does not identify a continuing IXIFI-specific patent dispute that materially changes its current commercial profile. The principal legal risk is therefore residual protection around manufacturing, formulation, or method-of-use claims, rather than a credible return to Remicade-style market exclusivity.

What is the FDA regulatory status of IXIFI?

IXIFI is FDA-approved as a biosimilar to Remicade. It does not have an FDA interchangeability designation. That distinction matters because a biosimilar may be prescribed in accordance with its approved labeling, but automatic pharmacy-level substitution depends on state law and, in many cases, an FDA interchangeability designation.

For IXIFI, treatment decisions remain concentrated among prescribers, infusion centers, health systems, and payers. The lack of interchangeability designation limits automatic substitution compared with interchangeable biologics, although payer policies can still drive switching or new-patient starts.

IXIFI is not an Orange Book-listed product because the Orange Book is primarily used for approved small-molecule drugs. Its biologic status is evaluated through the Purple Book and the biologics regulatory framework. (U.S. Food and Drug Administration, 2024)

What generic or biosimilar launch risks exist for IXIFI?

IXIFI does not face conventional generic-drug entry. It faces biosimilar competition and possible additional infliximab biosimilar launches.

The main commercial scenarios are:

Scenario	Market effect on IXIFI
Stable multi-biosimilar market	Continued price pressure with share determined by contracts
Payer-preferred competitor	Loss of infusion-center and physician-office volume
Interchangeable infliximab entrant	Greater automatic-substitution pressure
Supply disruption at a competitor	Temporary share gain for IXIFI if Pfizer has available capacity
Remicade contracting response	Lower market prices and reduced biosimilar margins
Expanded inflammatory-disease treatment volume	Higher total units but limited pricing benefit
Manufacturing or quality event	Rapid provider switching and contract loss

An interchangeable competitor would pose a greater substitution risk than a non-interchangeable biosimilar. IXIFI’s current exposure is primarily economic rather than patent-based.

How does IXIFI compare financially with Inflectra?

Inflectra has the stronger commercial position within Pfizer’s infliximab portfolio because it entered the U.S. market earlier and had more time to establish contracts, utilization history, and provider familiarity.

Factor	IXIFI	Inflectra
U.S. approval	2017	2016
Sponsor	Pfizer	Pfizer / Hospira
Same active molecule	Yes	Yes
Market entry timing	Later	Earlier
Portfolio overlap	High	High
Interchangeability	No	No
Likely strategic role	Supplemental portfolio product	Core infliximab biosimilar brand
Separate revenue disclosure	No	Generally not separately disclosed

The overlap reduces IXIFI’s ability to command a premium. Pfizer may use both products to support supply flexibility or contracting, but the portfolio structure also risks cannibalization.

What revenue exposure does IXIFI create for Pfizer?

IXIFI creates limited direct revenue transparency and moderate strategic exposure.

Its revenue exposure is affected by:

• Pfizer’s ability to secure contracts against Inflectra and Renflexis
• Net price erosion in U.S. infliximab
• International tender outcomes
• Capacity utilization at Pfizer and contract manufacturers
• Payer switching policies
• The growth of biosimilar adoption in gastroenterology and rheumatology

IXIFI’s downside is asymmetric. A price cut can reduce margins across the category, while a supply advantage can produce only temporary share gains. The product’s economic value depends on portfolio scale rather than standalone brand pricing.

How strong is the IXIFI patent estate?

IXIFI’s own patent position is less important than the expired and residual patent estate surrounding Remicade and infliximab manufacturing.

Patent-strength factor	Assessment
Core molecule exclusivity	Weak after Remicade composition patent expiry
Formulation differentiation	Limited publicly visible differentiation
Method-of-use protection	Potentially relevant by indication, but difficult to use as a broad market barrier
Manufacturing know-how	Meaningful operational protection
Regulatory exclusivity	Expired for the relevant reference-product period
Automatic substitution protection	No interchangeability designation
Long-term blocking power	Low relative to the original Remicade estate

The estate is therefore commercially defensible through manufacturing, contracts, and supply rather than through a broad blocking patent.

Key Takeaways

• IXIFI is Pfizer’s infliximab-qbtx biosimilar to Remicade, approved by the FDA in December 2017.
• Pfizer does not disclose IXIFI revenue or profitability separately.
• IXIFI entered a market already occupied by Inflectra and Renflexis.
• Inflectra likely has the stronger Pfizer commercial position because it entered earlier and had greater time to establish contracts.
• Remicade’s principal U.S. composition patent expired in 2018, shifting market risk from patent blocking to price and contracting pressure.
• IXIFI is not FDA-designated interchangeable and is not listed in the Orange Book.
• The product’s long-term value depends on net price, payer access, supply reliability, and Pfizer’s broader biosimilar portfolio.
• The main future threat is additional biosimilar and potentially interchangeable infliximab competition, not conventional generic entry.

FAQs About IXIFI Market and Financial Outlook

Is IXIFI still commercially important to Pfizer?

IXIFI remains strategically relevant as part of Pfizer’s biosimilar portfolio, but Pfizer does not report it as a major standalone revenue product.

Does IXIFI have an FDA interchangeability designation?

No. IXIFI is FDA-approved as a biosimilar to Remicade but does not have an interchangeability designation.

Is IXIFI listed in the Orange Book?

No. Biologics such as IXIFI are tracked through the FDA Purple Book rather than the Orange Book.

What drug competes most directly with IXIFI?

The closest U.S. competitors are Inflectra and Renflexis, both infliximab biosimilars with the same reference product, Remicade.

Could an interchangeable infliximab biosimilar materially reduce IXIFI sales?

Yes. An interchangeable product could increase automatic substitution and intensify payer and provider pressure on non-interchangeable infliximab biosimilars.

References

1. Johnson & Johnson. (2018). 2017 annual report. https://www.jnj.com
2. Johnson & Johnson. (2021). 2020 annual report. https://www.jnj.com
3. Johnson & Johnson. (2023). 2022 annual report. https://www.jnj.com
4. U.S. Food and Drug Administration. (2017). IXIFI (infliximab-qbtx) prescribing information and approval materials. https://www.fda.gov
5. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov
6. U.S. Patent No. 6,284,471. (2001). Human antibodies that bind human TNF-alpha. United States Patent and Trademark Office.